Absorbable bioplatforms are considered safe and effective in stable patients but their use in the context of acute myocardial infarction with ST segment elevation has not been reported. Low risk of heart attack with low Killip classification could be the stage for this device. 87 consecutive patients experiencing myocardial infarction with ST elevation underwent primary angioplasty at a center between December 2012 and May 2013 of which 25.3% received the new platform. The device was implanted properly in 96.4% of injuries, only one device could not be implemented due to vessel tortuosity. 90.5% of patients ended up with a TIMI 3 flow and 9.5% with TIMI 2. One patient had definitive thrombosis from the device, associated with double anti-aggregation holdup. At five months follow-up there were no cases of clinical restenosis and the rate of in-hospital events and mortality was zero.
Conclusion: Bioabsorbable implant platforms in the context of primary angioplasty appears safe.
Petr Widimsky, MD.
2013-05-22
Original title: Bioresorbablestents in acute STEMI – PilotAbsorb-STEMI Registry (PRAGUE 19).
